Tag: PLCγ2
-
How Remibrutinib May Control Multiple Sclerosis Through BTK Inhibition
Remibrutinib inhibits Bruton’s tyrosine kinase in B cells and myeloid cells, suppressing downstream immune signaling without directly depleting B cells. This mechanism differentiates BTK inhibitors from anti-CD20 therapies and may influence both peripheral inflammation and CNS neuroinflammation in multiple sclerosis.